transplant Program, toronto general Hospital, toronto, Ontario, canada; and 3 Department of anesthesiology, toronto general Hospital, toronto, Ontario, canada Portal vein thrombosis (PVt) is a severe complication after liver transplantation that can result in increased morbidity and mortality. Few data are available regarding risk factors, classification, and treatment of PVt after living donor liver transplantation (lDlt). Between January 2004 and november 2014, 421 adult-to-adult lDlts were performed at our institution, and they were included in the analysis. Perioperative characteristics and outcomes from patients with no-PVt (n = 393) were compared with those with de novo PVt (total portal vein thrombosis [t-PVt]; n = 28). ten patients had early portal vein thrombosis (e-PVt) occurring within 1 month, and 18 patients had late portal vein thrombosis (l-PVt) appearing later than 1 month after lDlt. analysis of perioperative variables determined that splenectomy was associated with t-PVt (hazard ratio [Hr], 3.55; P = 0.01), e-PVt (Hr, 4.96; P = 0.04), and l-PVt (Hr, 3.84; P = 0.03). in contrast, donor age was only found as a risk factor for l-PVt (Hr, 1.05; P = 0.01). Salvage rate for treatment in e-PVt and l-PVt was 100% and 50%, respectively, without having an early event of rethrombosis. Mortality within 30 days did not show a significant difference between groups (no-PVt, 2% versus e-PVt, 10%; P = 0.15). no significant differences were found regarding 1-year (89% versus 92%), 5-year (79% versus 82%), and 10-year (69% versus 79%) graft survival between the t-PVt and no-PVt groups, respectively (P = 0.24). the 1-year (89% versus 96%), 5-year (82% versus 86%), and 10-year (79% versus 83%) patient survival was similar for the patients in the no-PVt and t-PVt groups, respectively (P = 0.70). no cases of graft loss occurred as a direct consequence of PVt. in conclusion, the early diagnosis and management of PVt after lDlt can lead to acceptable early and longterm results without affecting patient and graft survival. Portal vein thrombosis (PVT) is a severe problem following liver transplantation (LT) that can be potentially devastating and lead to graft failure. It represents an important source of morbidity and mortality especially if it occurs in the early postoperative period. (1) (2) (3) The incidence of PVT in deceased donor liver transplantation (DDLT) ranges from 0.3% to 2.6%. (3) (4) (5) Duffy et al. reported a large clinical study, with an overall PVT incidence of 2% in more than 4200 patients after LT. (6) The rate of PVT increases to between 4% and 9% in adult-to-adult living donor liver transplantation (LDLT) due to more complex surgical techniques and complicated vascular reconstructions, mainly related to shorter vessel grafts resulting in a reduced vessel length for anastomosis. (6) (7) (8) (9) (10) (11) There are numerous studies in which the risk factors for PVT after deceased and pediatric LT have been reported.
Portal vein thrombosis (PVT) is a severe problem following liver transplantation (LT) that can be potentially devastating and lead to graft failure. It represents an important source of morbidity and mortality especially if it occurs in the early postoperative period. (1) (2) (3) The incidence of PVT in deceased donor liver transplantation (DDLT) ranges from 0.3% to 2.6%. (3) (4) (5) Duffy et al. reported a large clinical study, with an overall PVT incidence of 2% in more than 4200 patients after LT. (6) The rate of PVT increases to between 4% and 9% in adult-to-adult living donor liver transplantation (LDLT) due to more complex surgical techniques and complicated vascular reconstructions, mainly related to shorter vessel grafts resulting in a reduced vessel length for anastomosis. (6) (7) (8) (9) (10) (11) There are numerous studies in which the risk factors for PVT after deceased and pediatric LT have been reported.
The most common causes of PVT described after DDLT are technical errors related to venous redundancy, kinking, and/or stenosis of the anastomosis. (5) Additional risk factors include prior surgery on the portal or splanchnic venous system or a pretransplant portal thrombosis requiring thrombectomy during the operation, a small diameter of the portal vein (PV; <5 mm), previous splenectomy, hypoplastic PV, large portosystemic collaterals, and the use of vascular grafts for PV reconstruction. (5, (12) (13) (14) (15) There are only a few published studies investigating PVT in adult-to-adult LDLT in which graft position, pretransplant PVT, and the use of a vascular graft have been described as risk factors to the development of PVT. The previous studies are limited because of the small sample size and the combination of the de novo PVT population with the pretransplant existing PVT population. (7, 16, 17) In this study, we investigated the impact of de novo PVT on the outcome of adult-to-adult LDLT with right hemilivers in a large, single-center North American population. We also evaluated risk factors for PVT and possible treatment strategies.
Patients and Methods

StUDY DESIGN
This study received a priori approval by the local institutional review board through the Coordinated Approval Process for Clinical Research system (CAPCR #16-5534). The data were prospectively collected. Patients receiving adult-to-adult LDLTs with right lobe liver grafts occurring between January 2004 and November 2014 at our institution were retrospectively analyzed for this study. Doppler ultrasound and computed tomography (CT) scan images after LDLT were reviewed to identify the moment and extension of PVT. Recipients with either intraoperative or preoperative findings of PVT were excluded from this study as a confounding factor. Therefore, outcomes of the total number of patients with a de novo event of PVT (total portal vein thrombosis [t-PVT]; n = 28) were compared with all patients without PVT (no-PVT; n = 393) following LDLT during the same time period. In a subset analysis, the t-PVT group was divided into 2 subgroups: early portal vein thrombosis (e-PVT) for those cases occurring within 1 month after LDLT and late portal vein thrombosis (l-PVT) for those appearing later than 1 month. These subgroups were also compared with the no-PVT group regarding the potential risk factors for PVT.
At the University of Toronto, regardless of their disease etiology, disease severity, or Model for End-Stage Liver Disease (MELD) score, all patients included on the waiting list for DDLT are also offered the option of LDLT. Donors and recipients are informed about the expected outcomes according to past and present data from our institution. (18, 19) 
DoNoR AND RECIPIENt DEMoGRAPHICS
Recipient demographics and preoperative variables were identified, including the following: sex, age, body mass index (BMI), underlying liver disease, MELD score, biochemical profile, and time on the waiting list. Furthermore, demographic and preoperative data from donors were also investigated, incorporating the following: age, sex, and BMI (Table 1) .
GRAFt AND INtRAoPERAtIvE CHARACtERIStICS
Living donor hepatectomy and organ procurement for LDLT were performed as described in our prior studies. (20) Graft and intraoperative characteristics were collected, including graft-to-recipient weight ratio (GRWR), grafts with the middle hepatic vein, cold ischemia time (CIT), warm ischemia time (WIT), surgical time, anhepatic phase time, estimated blood loss, transfusions, tranexamic acid and vasopressin administration, splenectomy, international normalized ratio (INR), partial thromboplastin time (PTT), fibrinogen levels, and antibody induction therapy.
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During the recipient's surgery, the first choice for biliary reconstruction was duct-to-duct anastomosis when it was technically possible. Roux-en-Y biliary reconstruction was performed in those patients with underlying primary sclerosing cholangitis (PSC) and/ or with 2 or more bile ducts.
The decision of whether the middle hepatic vein was included in the graft depended on the drainage of segments IV, V, and VIII and the residual graft volume. (20) Splenectomy was performed at the time of LDLT (n = 15) if the risk for small-for-size syndrome (SFSS) was considered high (low GRWR, higher spleen volume, severity of portal hypertension prior to transplant, macroscopic congestion after reperfusion, low hepatic artery flow and high PV inflow after reperfusion) or if a hematologic indication was present (idiopathic thrombocytopenic purpura [n = 1] and hemolytic anemia [n = 1]). Alternatively, splenectomy was performed during a second surgery (n = 9) if signs of SFSS occurred (high bilirubin [>10 mg/dL], coagulopathy [INR > 2] , intractable ascites and/or encephalopathy grade 3/4). SFSS was considered the diagnosis only if arterial or portal occlusion, outflow congestion, bile leak, rejection, or septic complication had been excluded. NOTE: Data are given as n (%), mean (±SD), and median (range).
The median time from LDLT to the second surgery for splenectomy was 5 days (2-12 days). Notably, splenectomy was additionally performed following LDLT in cases of refractory ascites (n = 2), distal pancreatic tumor (n = 1), and trauma (n = 1).
All of the patients who were subjected to splenectomy received initial anticoagulation with nonfractionated heparin followed by longterm fractionated heparin or warfarin.
IMAGING PRotoCoL FoR vASCULAR PAtENCY AFtER Lt
Doppler ultrasound was performed routinely on the first and third postoperative day following LDLT. If a clinical anomaly was identified (elevated hepatic enzymes, hyperbilirubinemia, moderate ascites, abdominal pain, or persistently elevated INR), additional Doppler ultrasound or triphasic angio-CT scan was performed to identify or exclude vascular thrombosis.
SHoRt-tERM AND LoNGtERM oUtCoME
Posttransplantation levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) at 7 days, 1 month, 3 months, and 1 year following transplantation were investigated as markers of hepatocyte injury. Liver function was determined by INR and bilirubin levels at the same posttransplantation time points.
The recipients' short-term outcomes were evaluated by postoperative hospital stay, intensive care unit (ICU) stay, as well as postoperative complications and mortality occurring within 30 days following transplantation. Complications were graded according to ClavienDindo classification. (21) Major complications were defined as ≥3b. Incidence of hepatic artery thrombosis was also recorded. Additionally, all episodes of bacterial infection and pneumonia were registered. Events of acute graft rejection, biliary complications (including biliary leak and biliary stricture), and retransplantation within the first year were also documented.
Longterm outcomes were evaluated by graft and patient survival at 1, 5, and 10 years after transplantation.
SFSS DIAGNoSIS AND MANAGEMENt
At our institution, in those patients who develop signs of liver insufficiency (high bilirubin [>10 mg/ dL], coagulopathy [INR > 2], intractable ascites, and/ or encephalopathy grade 3/4) after LDLT, we consider SFSS as a differential diagnosis. Before a SFSS diagnosis is established, arterial or portal occlusion, outflow congestion, bile leak, rejection, or septic complication should be excluded.
In our transplantation unit, every patient with signs of SFSS undergoes a Doppler ultrasound and/or CT scan to rule out vascular complications. Following exclusion of inflow or outflow vascular complications, sepsis screening and a liver biopsy to exclude rejection are performed. Once the diagnosis is established, surgical or medical treatment is initiated. Therefore, in addition to treating each of the signs of liver failure (eg, encephalopathy, coagulopathy), patients are started on an octreotide infusion and receive wide-spectrum antibiotics because these patients are prone to bacterial translocation and consequent sepsis. Moreover, if the diagnosis of SFSS is established after LDLT, the patient is taken back to the operating room to perform a PV flow modulation procedure (eg, splenectomy or splenic artery ligation).
In the studied timeframe (2004-2014), 27 patients developed signs of SFSS. Twenty-four (88%) of the patients underwent splenectomy for PV flow modulation. Splenectomy was performed during LDLT in 15 patients and after transplantation in 9 patients. Additionally, 3 patients were subjected to splenic artery ligation during LDLT as the modulation technique. All of the patients underwent an anticoagulation regimen with nonfractionated heparin for 1-3 weeks followed by longterm fractioned heparin or warfarin.
In order to decrease the incidence of SFSS at our institution, in addition to size, we consider the graft quality. For this reason, in small-sized grafts, further risk factors that could contribute to SFSS such as older donor age, higher donor BMI, and graft steatosis are avoided. Furthermore, at our center, we exclude the use of small-sized grafts for patients with severe portal hypertension, renal replacement therapy, high MELD score, fulminant hepatic failure, or patients intubated requiring intensive care. (22, 23) 
StAtIStICAL ANALYSIS
The data were analyzed with SPSS, version 23 (IBM, Chicago, IL). Data were presented as median (range) or mean (±standard deviation [SD] ). Continuous variables were compared by using either t test or MannWhitney U analyses depending on if the variables were normally or nonnormally distributed, respectively.
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Differences between categorical variables were assessed with chi-square and Fisher's test as required.
A univariate Cox proportional hazards regression model of the clinically associated variables was used, and significant variables with a P value ≤ 0.10 were designated for the multivariate analysis of potential risk factors for PVT.
The Kaplan-Meier method was used for patient and graft survival analysis, and groups were compared with log-rank test. In all the tests, a P value of <0.05 was contemplated as significant.
results
From 2004 to 2014, 430 patients received a right lobe adult-to-adult LDLT at Toronto General Hospital, University of Toronto. Among these, 9 patients were excluded from the study due to the preoperative or intraoperative finding of a PVT. A total of 421 patients were included for the final analysis. From this group, a total of 28 patients developed a new PVT (t-PVT) following LDLT. The t-PVT group (n = 28) was compared with the patients without PVT (no-PVT) event (n = 393) during the same period of time. Median follow-up was 55 versus 71 months for the no-PVT and t-PVT group, respectively.
tYPES oF Pvt AND tIMELINE oF DEtECtIoN
De novo PVT after transplantation was detected in a total of 28 (6.7%) patients. From these, 10 (2.4%) patients were classified as e-PVT occurring within 1 month after LDLT, and 18 (4.3%) patients as l-PVT appearing later than 1 month; e-PVT occurred after a median of 5 days (range, 1-30 days). A total of 7 out of 10 patients of e-PVT occurred within the first 7 days after transplantation. In contrast, l-PVT occurred after a median of 28 months (range, 2-81 months). A total of 5 out of 18 patients of l-PVT occurred within the first year after transplantation.
Interestingly, from the total of patients with PVT (n = 28), only 18 patients presented extrahepatic PVT, and 10 patients were found with only intrahepatic segmental PVT.
According to classifications in Table 2 , the e-PVT subgroup was classified as grade I, grade II, and grade III-p in 4, 2, and 2 patients, respectively. Two more patients developed segmental e-PVT without extension to the main PV ( Fig. 1) Furthermore, the l-PVT subgroup was also categorized following the classification in Table 2 . The late events of PVT were categorized as grade I (5 patients), grade III-p (4 patients), and grade IV-t (1 patient). Moreover, segmental PVT was identified in 8 patients (Fig. 2) . No extension of thrombosis toward the main PV or another segment was seen in any case of segmental l-PVT.
RISK FACtoRS FoR Pvt (UNIvARIAtE ANALYSIS)
The total study population was divided into 2 groups: patients with de novo PVT (t-PVT) compared against the group of patients who did not develop PVT (no-PVT). The comparison of preoperative variables showed that the groups were homogeneous in most of the characteristics, including the following: recipient age, recipient and donor BMI, percentage of male recipients, preoperative MELD score, diagnosis before transplantation, CIT and WIT, as well as antibody induction (Table 1) . Analysis showed a lower GRWR in the t-PVT versus no-PVT group (1.08 ± 0.28 versus 1.16 ± 0.35; P = 0.26) without significant differences between groups. Interestingly, a GRWR of <0.8% was observed significantly more frequently in patients with the t-PVT versus no-PVT groups (21% versus 11%; P = 0.04). Notably, there was not a difference in the no-PVT versus t-PVT groups for the use of hemilivers with the middle hepatic vein (24% versus 14%; P = 0.35; Table 1 ).
Analysis for intraoperative characteristics demonstrated that platelet transfusion was higher in the 
FIG. 1.
Breakdown of e-PVT cases. All the events of e-PVT were initially treated with nonfractionated heparin as infusion or subcutaneous administration and then adjusted according to the PTT until it reached 1.5 to 2 times the normal values. Anticoagulation with nonfractionated heparin was kept for 1-3 weeks. It was then followed by low-molecular-weight heparin or warfarin (adjustments according to INR). Note: 1 patient in the grade I group did not receive anticoagulation due to hemorrhagic stroke.
FIG. 2.
Breakdown of l-PVT cases. In the event of l-PVT, anticoagulation with nonfractionated heparin was started just in those cases where there was an acute elevation of liver enzymes, ascites, or a new onset of abdominal pain. It was then followed with longterm anticoagulation as described in the e-PVT case. If the l-PVT was an incidental finding from a routine Doppler ultrasound without another additional clinical alteration, warfarin was initiated according to the risk of extension and progression of the thrombosis.
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RISK FACtoRS FoR E-Pvt AND L-Pvt (UNIvARIAtE ANALYSIS)
As a subset evaluation, analysis of potential risk factors was performed for the e-PVT and l-PVT subgroups compared with the no-PVT group (Tables 3 and 4 ). In the case of the e-PVT subgroup, the percentage of patients with a GRWR of <0.8% was higher in the e-PVT versus no-PVT group, but no significant difference was found (30% versus 11%; P = 0.07). No difference was found in the number of patients who received a hemiliver with a middle hepatic vein in the no-PVT versus e-PVT groups (24% versus 20%; P > 0.99) and the no-PVT versus l-PVT group (24% versus 11%; P = 0.11). Of interest, the number of units of platelets transfused during transplantation was significantly higher in the e-PVT group when compared with the no-PVT group (5 ± 11 versus 2 ± 3 units; P = 0.002). Furthermore, the percentage of splenectomy was also significantly higher in the e-PVT versus the no-PVT group (40% versus 6%; P = 0.001; Table 3 ).
On the other hand, analysis for the l-PVT subgroup showed that the percentage of patients with PSC was higher in the l-PVT versus no-PVT group (28% versus 14%; P = 0.09). Interestingly, in this analysis, the donors were significantly older in the l-PVT group versus the no-PVT group (45 ± 10 versus 37 ± 11 years; P = 0.01). Moreover, the percentage of splenectomy was also found significantly higher in the l-PVT group compared with the no-PVT group (17% versus 6%; P = 0.02; Table 4 ).
MULtIvARIAtE ANALYSIS oF RISK FACtoRS FoR Pvt
We performed a multivariate Cox proportional hazards regression analysis to identify independent risk factors for t-PVT, e-PVT, and l-PVT. Factors with a P value of <0.10 (P < 0.10) in the univariate analysis were used for the multivariate model.
The t-PVT group was initially evaluated taking into account potential risk factors from the univariate analysis. The univariate analysis found a significantly higher percentage of cases with a GRWR < 0.8% (21% NOTE: Data are given as n (%), mean (±SD), and median (range).
versus 11%; P = 0.04) as well as a significantly higher percentage of patients with splenectomy (25% versus 6%; P = 0.001) in the t-PVT versus the no-PVT group. After performing a multivariate analysis, the only variable that continued independently associated with the event of t-PVT was splenectomy (P = 0.01; hazard ratio [HR], 3.55; B = 1.26; 95% confidence interval [CI] = 1.28-9.83; Table 1 ). Additional analyses were performed to evaluate variables that were associated with e-PVT. As demonstrated in the univariate analysis, significantly more units of platelets were transfused (5 ± 11 versus 2 ± 3 units; P = 0.002) as well as a significantly higher percentage of splenectomies (40% versus 6%; P = 0.001) were performed in the e-PVT versus no-PVT groups. In contrast, multivariate analysis of potential risk factors showed that only splenectomy continued being independently associated with the development of e-PVT (P = 0.04, HR, 4.96; B = 1.60; 95% CI, 1.07-22.95; Table 3 ).
Finally, a multivariate Cox regression analysis was implemented to determine risk factors for the development of l-PVT. As previously stated, univariate analysis demonstrated that donors were significantly older (45 ± 10 versus 37 ± 11; P = 0.01) and had a significantly higher percentage of splenectomies (17% versus 6%; P = 0.02) in the l-PVT versus no-PVT groups. Interestingly, multivariate analysis of the clinically and statistically significant variables for l-PVT determined that both donor age (P = 0.01; HR, 1.05; B = 0.06; 95% CI, 1.01-1.10) and splenectomy (P = 0.03; HR, 3.84; B = 1.34; 95% CI, 1.09-13.44) were independently associated with an episode of l-PVT (Table 4) .
tREAtMENt AND oUtCoMES
Two patients with e-PVT presented with a complete absence of portal venous flow (grade II). Thrombectomy and Fogarty catheter thrombus extraction followed by heparin sodium treatment was performed. None of the cases used a vascular jump graft. Both grafts were saved, and the patients recovered. In all of the other cases, if e-PVT presented with partial thrombosis and preserved flow (grade I, grade III-p, grade IVp), anticoagulation with heparin sodium was started either as an infusion or via subcutaneous administration and was then adjusted according to the activated PTT until it reached 1.5 to 2 times the normal values. Anticoagulation with heparin sodium was kept for 1-3 weeks. It was followed by low-molecular-weight Original article | 1217 heparin or warfarin (adjustments according to INR). PV patency was assessed with Doppler ultrasound every 2-3 months and complemented with a CT scan as required (Fig. 1) .
In the event of l-PVT, anticoagulation with heparin sodium was started only in the cases where there was an acute elevation of liver enzymes (3 patients), ascites (2 patients), or a new onset of abdominal pain (2 patients). It was followed with longterm anticoagulation as described in the case of an e-PVT. If the l-PVT was an incidental finding from a routine Doppler ultrasound without another additional clinical alteration, warfarin was initiated according to the risk of the extension and progression of the thrombosis. Of interest, there was only 1 patient with a total occlusion of flow through the portal system (grade IV-t) but with multiple collaterals toward the liver; the rest of the cases showed only partial thrombosis of the portal system (grade I, grade III-p, and segmental).
Immediate postoperative outcomes were found to be similar for the t-PVT group when compared with the no-PVT group (Supporting Table 1 ). Of interest, liver injury and function at 1 month following transplantation were comparable for both groups except for a significantly higher level of total bilirubin (TBil; 2.63 ± 3.45 versus 1.75 ± 2.69 mg/dL; P = 0.01) as well as higher levels of ALP (336 ± 320 versus 198 ± 158 U/L; P = 0.01) in the t-PVT versus no-PVT groups. This finding persisted 1 year after transplantation when the levels of TBil were significantly higher in the t-PVT group when compared with the no-PVT group (1.93 ± 2.75 versus 0.94 ± 1.7 mg/dL; P = 0.02), in this case correlating with the occurrence of l-PVT (Supporting Table 1 ).
Analysis of the rest of the postoperative outcomes demonstrated that the percentage of Clavien-Dindo ≥ 3b and general complications within 30 days after transplantation were similar for both groups. In addition, events of arterial thrombosis, ICU stay, stepdown stay, hospital stay, biliary complications, and graft rejection did not show any difference between the 2 groups. The percentage of overall retransplantation and retransplantation within 1 year was comparable for both groups (Supporting Table 2 ).
Patients in the t-PVT and no-PVT groups had similar 1-year (89% versus 92%), 5-year (79% versus 82%), and 10-year (60% versus 79%) graft survival rates (P = 0.24; Fig. 3) . Furthermore, the 1-year (89% versus 96%), 5-year (82% versus 86%), and 10-year (79% versus 83%) patient survival rates were identical for the patients from the t-PVT versus no-PVT groups (P = 0.70; Fig. 4) .
Four patients from the t-PVT group needed retransplant due to a recurrence of underlying disease.
FIG. 3.
Graft survival after transplantation. The percentage of graft survival was similar in both groups, and no significant difference was found between no-PVT and t-PVT at 1 (92% versus 89%), 5 (82% versus 79%), and 10 (79% versus 69%) years, respectively, after transplantation (P = 0.24). Analysis performed with Kaplan-Meier method with log-rank test.
FIG. 4.
Patient survival after transplantation. The percentage of patient survival was similar in both groups, and no significant difference was found between no-PVT and t-PVT at 1 (96% versus 89%), 5 (86% versus 82%), and 10 (83% versus 79%) years, respectively, after transplantation (P = 0.70). Analysis performed with Kaplan-Meier method with log-rank test.
From these patients, 2 had recurrence of cirrhosis due to hepatitis C infection, 1 patient had recurrent PSC, and 1 patient had acute intermittent porphyria. All of these retransplants were performed more than 3 years after the initial transplant. There were no cases of graft loss as a direct consequence of PVT.
Discussion
The worldwide success of LT has resulted in an increased demand with a subsequent shortage of deceased donor organs. LDLT is an attractive strategy to provide additional high quality grafts to the donor pool and improve the organ shortage. (11) LDLT is a more complicated procedure than DDLT mainly due to its technical complexity and different hemodynamic, physiological, and anatomical requirements resulting from the graft characteristics and liver regeneration. (24) (25) (26) The technique's complexity leads to an increased occurrence of vascular complications. In this study, we found that the rate of extrahepatic PVT in our center (4.3%) was comparable with a series from Asia (3.4%), (27) where this procedure is the main source for adult LT, and lower than in other reports from North America that reach up to 11%. (6, 28, 29) The treatment of cases with PVT in our center varied depending on the grade of thrombosis and according to the clinical presentation. Only 2 out of the 28 patients with PVT were resolved by surgery with thrombectomy and the use of a Fogarty catheter. The indication was the absence of flow through the PV (grade II). Both grafts were saved and did not require additional surgical intervention. The patients with early PVT other than grade II who were stable during follow-up were treated with anticoagulation as described in the Results. This approach led to a 100% resolution in the patients with early PVT and a classification other than grade II. Our results are in contrast with other reports from the literature where surgical intervention, thrombolysis, or stent placement was performed in most of the cases of early thrombosis. (6, 7, (30) (31) (32) On the other hand, l-PVT was treated with heparin sodium only in the cases where clinical repercussion (elevated hepatic enzymes, abdominal pain, or ascites) accompanied the findings of PVT. If the l-PVT was an incidental finding from a routine Doppler ultrasound without another additional clinical alteration, then warfarin was initiated according to the risk of extension and progression of the thrombosis. This approach reached 50% of the salvage rate in the treated patients. Patients who did not receive anticoagulation (10 patients) were either patients with extrahepatic PVT who were stable with adequate liver flow through collaterals or patients with small segmental PVT without clinical or hepatic enzyme alterations. These patients were subsequently assessed with Doppler ultrasound without the extension of PVT.
In our study, early segmental PVT with biochemical signs of hepatocyte injury was managed with anticoagulation, resulting in good outcomes with 100% resolution without recurrence. In contrast, the management of late events of segmental PVT was only considered for anticoagulation in the case of acute changes of patient clinical status. None of the segmental PVTs that were not treated evolved to an extension into the main PV or toward the other segments. During the follow-up of patients with segmental PVT, no cases of cholangitis accompanied the thrombotic event as described in a preceding small series of cases. (33) In relation to risk factors for developing PVT, our analysis demonstrated an independent association of splenectomy with the event of either e-PVT or l-PVT as described in previous studies on DDLT. (6, 34) Hemodynamic changes, endothelial injury, and decreased portal venous flow might contribute to develop the thrombosis, and anticoagulation should be performed after splenectomy. In our series, 7 out of 30 patients who had splenectomy developed PVT despite initial anticoagulation with heparin following the procedure. Although splenectomy was found to be a factor associated with e-PVT and l-PVT in our series, we certainly believe that the benefit of avoiding SFSS and secondary graft loss justifies a splenectomy when considered necessary. Of interest, older donor age was associated with the development of l-PVT, a finding that had not been reported before.
Independently of the risk factors that were associated with the development of PVT, early identification and management led to the avoidance of retransplantation as a consequence of PVT.
Regarding the short-term and longterm outcomes, this study demonstrated no significant difference in graft survival in patients with PVT when compared with those without PVT. This result is opposite to what is reported in the literature in LDLT and also deceased transplantation. (2, 3, 6, 17, 35) In the same manner, patient survival was not impacted after the episode of PVT contrary to results from previous studies. (2, 3, 6, 17, 35) These findings can be related to the higher incidence of concomitant hepatic artery thrombosis of up to 17% in some reports (6, 7) and the heterogeneity of the sample in those series that includes pediatric patients (4, 6) and a longer period of study time. (6) Therefore, according to our results, a close follow-up of the patients after LDLT can lead to an early identification and successful treatment of e-PVT and l-PVT without affecting the short-term and longterm outcomes. The results of this study also suggest that the patients who are subjected to splenectomy either at the time of LDLT or after transplant are at an increased risk of PVT and should be put under an anticoagulation regimen and close surveillance. We also believe that the recipients of older grafts in combination with other risk factors (eg, splenectomy, hypercoagulable state) require a closer follow-up to identify potential new events of PVT. This is the largest single-center LDLT series of cases reported in which the incidence, classification, risk factors, and outcomes following PVT have been studied. The strength of this study is a homogeneous population by using only right lobe grafts in the setting of adult-to-adult LDLT and by excluding preexisting PVT. Moreover, this is the first report that includes the analysis and treatment of segmental PVT and its outcomes. In addition, all patients were treated with a standardized protocol for donor selection, surgical procedures, and medical procedures together with a long follow-up period that provided consistent data. Shortcomings of this study include the small number of PVTs and the retrospective study design.
In conclusion, PVT is a severe complication after LDLT but its early diagnosis and management can lead to excellent short-term and longterm results without affecting patient and graft survival.
